Skip to main content
AAN.com

Abstract

Background and Objectives

Chronic poststroke language impairment is typically worse in older individuals or those with large stroke lesions. However, there is unexplained variance that likely depends on intact tissue beyond the lesion. Brain age is an emerging concept, which is partially independent from chronologic age. Advanced brain age is associated with cognitive decline in healthy older adults; therefore, we aimed to investigate the relationship with stroke aphasia. We hypothesized that advanced brain age is a significant factor associated with chronic poststroke language impairments, above and beyond chronologic age, and lesion characteristics.

Methods

This cohort study retrospectively evaluated participants from the Predicting Outcomes of Language Rehabilitation in Aphasia clinical trial (NCT03416738), recruited through local advertisement in South Carolina (US). Primary inclusion criteria were left hemisphere stroke and chronic aphasia (≥12 months after stroke). Participants completed baseline behavioral testing including the Western Aphasia Battery–Revised (WAB-R), Philadelphia Naming Test (PNT), Pyramids and Palm Trees Test (PPTT), and Wechsler Adult Intelligence Scale Matrices subtest, before completing 6 weeks of language therapy. The PNT was repeated 1 month after therapy. We leveraged modern neuroimaging techniques to estimate brain age and computed a proportional difference between chronologic age and estimated brain age. Multiple linear regression models were used to evaluate the relationship between proportional brain age difference (PBAD) and behavior.

Results

Participants (N = 93, 58 males and 35 females, average age = 61 years) had estimated brain ages ranging from 14 years younger to 23 years older than chronologic age. Advanced brain age predicted performance on semantic tasks (PPTT) and language tasks (WAB-R). For participants with advanced brain aging (n = 47), treatment gains (improvement on the PNT) were independently predicted by PBAD (T = −2.0474, p = 0.0468, 9% of variance explained).

Discussion

Through the application of modern neuroimaging techniques, advanced brain aging was associated with aphasia severity and performance on semantic tasks. Notably, therapy outcome scores were also associated with PBAD, albeit only among participants with advanced brain aging. These findings corroborate the importance of brain age as a determinant of poststroke recovery and underscore the importance of personalized health factors in determining recovery trajectories, which should be considered during the planning or implementation of therapeutic interventions.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Lukic S, Thompson CK, Barbieri E, et al. Common and distinct neural substrates of sentence production and comprehension. Neuroimage. 2021;224:117374.
2.
Fridriksson J, Yourganov G, Bonilha L, Basilakos A, den Ouden DB, Rorden C. Revealing the dual streams of speech processing. Proc Natl Acad Sci USA. 2016;113(52):15108-15113.
3.
Thye M, Mirman D. Relative contributions of lesion location and lesion size to predictions of varied language deficits in post-stroke aphasia. NeuroImage Clin. 2018;20:1129-1138.
4.
Døli H, Andersen Helland W, Helland T, Specht K. Associations between lesion size, lesion location and aphasia in acute stroke. Aphasiology. 2021;35(6):745-763.
5.
Osa García A, Brambati SM, Brisebois A, et al. Predicting early post-stroke aphasia outcome from initial aphasia severity. Front Neurol. 2020;11:120.
6.
Fridriksson J, den Ouden DB, Hillis AE, et al. Anatomy of aphasia revisited. Brain. 2018;141(3):848-862.
7.
Ellis C, Urban S. Age and aphasia: a review of presence, type, recovery and clinical outcomes. Top Stroke Rehabil. 2016;23(6):430-439.
8.
Johnson L, Basilakos A, Yourganov G, et al. Progression of aphasia severity in the chronic stages of stroke. Am J Speech Lang Pathol. 2019;28(2):639-649.
9.
Murman DL. The impact of age on cognition. Semin Hear. 2015;36(03):111-121.
10.
Small BJ, Dixon RA, McArdle JJ. Tracking cognition–health changes from 55 to 95 years of age. J Gerontol B Psychol Sci Soc Sci. 2011;66B(Suppl 1):i153–i161.
11.
Stern Y, Barnes CA, Grady C, Jones RN, Raz N. Brain reserve, cognitive reserve, compensation, and maintenance: operationalization, validity, and mechanisms of cognitive resilience. Neurobiol Aging. 2019;83:124-129.
12.
Anatürk M, Kaufmann T, Cole JH, et al. Prediction of brain age and cognitive age: quantifying brain and cognitive maintenance in aging. Hum Brain Mapp. 2021;42(6):1626-1640.
13.
Elliott ML, Belsky DW, Knodt AR, et al. Brain-age in midlife is associated with accelerated biological aging and cognitive decline in a longitudinal birth cohort. Mol Psychiatry. 2019;26(8):3829-3838.
14.
Franke K, Gaser C. Longitudinal changes in individual BrainAGE in healthy aging, mild cognitive impairment, and Alzheimer's disease. GeroPsych. 2012;25(4):235-245.
15.
Franke K, Gaser C. Ten years of BrainAGE as a neuroimaging biomarker of brain aging: what insights have we gained? Front Neurol. 2019;10(JUL):789.
16.
Brett M, Leff AP, Rorden C, Ashburner J. Spatial normalization of brain images with focal lesions using cost function masking. Neuroimage. 2001;14(2):486-500.
17.
Nachev P, Coulthard E, Jäger HR, Kennard C, Husain M. Enantiomorphic normalization of focally lesioned brains. Neuroimage. 2008;39(3):1215-1226.
18.
Yourganov G, Fridriksson J, Rorden C, Gleichgerrcht E, Bonilha L. Multivariate connectome-based symptom mapping in post-stroke patients: networks supporting language and speech. J Neurosci. 2016;36(25):6668-6679.
19.
Kristinsson S, Basilakos A, den Ouden DB, et al. Predicting outcomes of Language rehabilitation (POLAR). Primary results from a large-scale aphasia therapy trial. In preparation.
20.
Kristinsson S, Basilakos A, Elm J, et al. Individualized response to semantic versus phonological aphasia therapies in stroke. Brain Commun. 2021;3(3):fcab174.
21.
Kertesz A. WAB-R: Western Aphasia Battery-Revised. PsychCorp; 2007.
22.
Roach A, Schwartz MF, Martin N, Grewal RS, Brecher A. The Philadelphia Naming Test: scoring and rationale. Clin Aphasio. 1996;24:121-133.
23.
Howard D, Patterson KE. The Pyramids and Palm Trees Test; 1992.
24.
Rorden C, McKinnon E, Hanayik T, Yourganov G, Reddy D. nii_preprocess: Zenodo DOI release. 2020.
25.
Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL. Neuroimage. 2012;62(2):782-790.
26.
Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26(3):839-851.
27.
Cole JH, Ritchie SJ, Bastin ME, et al. Brain age predicts mortality. Mol Psychiatry. 2018;23(5):1385-1392.
28.
Cole JH, Poudel RPK, Tsagkrasoulis D, et al. Predicting brain age with deep learning from raw imaging data results in a reliable and heritable biomarker. Neuroimage. 2017;163:115-124.
29.
Schnack HG, van Haren NE, Nieuwenhuis M, Hulshoff Pol HE, Cahn W, Kahn RS. Accelerated brain aging in schizophrenia: a longitudinal pattern recognition study. Am J Psychiatry. 2016;173(6):607-616.
30.
Pardoe HR, Cole JH, Blackmon K, Thesen T, Kuzniecky R. Structural brain changes in medically refractory focal epilepsy resemble premature brain aging. Epilepsy Res. 2017;133:28-32.
31.
Cole JH, Raffel J, Friede T, et al. Longitudinal assessment of multiple sclerosis with the brain-age paradigm. Ann Neurol. 2020;88(1):93-105.
32.
de Bézenac CE, Adan G, Weber B, Keller SS. Association of epilepsy surgery with changes in imaging-defined brain age. Neurology. 2021;97(6):e554–e563.
33.
Hickok G, Poeppel D. Dorsal and ventral streams: a framework for understanding aspects of the functional anatomy of language. Cognition. 2004;92(1-2):67-99.
34.
de Zubicaray GI, Rose SE, McMahon KL. The structure and connectivity of semantic memory in the healthy older adult brain. Neuroimage. 2011;54(2):1488-1494.
35.
Rice GE, Caswell H, Moore P, Hoffman P, Lambon Ralph MA. The roles of left versus right anterior temporal lobes in semantic memory: a neuropsychological comparison of postsurgical temporal lobe epilepsy patients. Cereb Cortex. 2018;28(4):1487-1501.
36.
Breitenstein C, Grewe T, Flöel A, et al. Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting. Lancet. 2017;389(10078):1528-1538.
37.
Hope TMH, Friston K, Price CJ, Leff AP, Rotshtein P, Bowman H. Recovery after stroke: not so proportional after all? Brain. 2019;142(1):15-22.
38.
Fridriksson J, Elm J, Stark BC, et al. BDNF genotype and tDCS interaction in aphasia treatment. Brain Stimul. 2018;11(6):1276-1281.
39.
Fridriksson J, Moser D, Bonilha L, et al. Neural correlates of phonological and semantic-based anomia treatment in aphasia. Neuropsychologia. 2007;45(8):1812-1822.
40.
Wilmskoetter J, Marebwa B, Basilakos A, et al. Long-range fibre damage in small vessel brain disease affects aphasia severity. Brain. 2019;142(10):3190-3201.
41.
Basilakos A, Stark BC, Johnson L, et al. Leukoaraiosis is associated with a decline in language abilities in chronic aphasia. Neurorehabil Neural Repair. 2019;33(9):718-729.
42.
Varkanitsa M, Peñaloza C, Charidimou A, Caplan D, Kiran S. White matter hyperintensities predict response to language treatment in poststroke aphasia. Neurorehabil Neural Repair. 2020;34(10):945-953.
43.
Liou LM, Chen CF, Guo YC, et al. Cerebral white matter hyperintensities predict functional stroke outcome. Cerebrovasc Dis. 2010;29(1):22-27.
44.
Liang Y, Chen YK, Liu YL, et al. Cerebral small vessel disease burden is associated with accelerated poststroke cognitive decline: a 1-year follow-up study. J Geriatr Psychiatry Neurol. 2019;32(6):336-343.
45.
Egorova N, Liem F, Hachinski V, Brodtmann A. Predicted brain age after stroke. Front Aging Neurosci. 2019;11:348.
46.
Steffener J, Habeck C, O'Shea D, Razlighi Q, Bherer L, Stern Y. Differences between chronological and brain age are related to education and self-reported physical activity. Neurobiol Aging. 2016;40:138-144.
47.
Kelly-Hayes M. Influence of age and health behaviors on stroke risk: lessons from longitudinal studies. J Am Geriatr Soc. 2010;58(SUPPL. 2):S325–S328.
48.
Lin Q, Huang WQ, Ma QL, et al. Incidence and risk factors of leukoaraiosis from 4683 hospitalized patients: a cross-sectional study. Medicine. 2017;96(39):e7682.
49.
Etherton MR, Wu O, Rost NS. Recent advances in leukoaraiosis: white matter structural integrity and functional outcomes after acute ischemic stroke. Curr Cardiol Rep. 2016;18(12):123.

Information & Authors

Information

Published In

Neurology®
Volume 100Number 11March 14, 2023
Pages: e1166-e1176
PubMed: 36526425

Publication History

Received: May 16, 2022
Accepted: October 31, 2022
Published online: December 16, 2022
Published in print: March 14, 2023

Permissions

Request permissions for this article.

Disclosure

The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Study Funding

National Institute on Deafness and Other Communication Disorders: R01DC014021, P50DC014664, and U01DC017521 (NIH/NIDCD).

Authors

Affiliations & Disclosures

From the Departments of Communication Sciences and Disorders (N.B., J.F.), and Psychology (C.R., R.N.N.), University of South Carolina, Columbia; Department of Health and Rehabilitation Sciences (J.W., E.G., S.K., J.F.), Medical University of South Carolina, Charleston; Department of Neurology (R.R., L.B.), Emory University, Atlanta, GA; Department of Neurology (A.E.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pharmacology and Therapeutics (S.S.K., C.d.B.), Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust (S.S.K., C.d.B.), Liverpool, United Kingdom.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Janina Wilmskoetter, PhD
From the Departments of Communication Sciences and Disorders (N.B., J.F.), and Psychology (C.R., R.N.N.), University of South Carolina, Columbia; Department of Health and Rehabilitation Sciences (J.W., E.G., S.K., J.F.), Medical University of South Carolina, Charleston; Department of Neurology (R.R., L.B.), Emory University, Atlanta, GA; Department of Neurology (A.E.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pharmacology and Therapeutics (S.S.K., C.d.B.), Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust (S.S.K., C.d.B.), Liverpool, United Kingdom.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIH/NIDCD U01DC017521, Co-Investigator, 2022(2) NIH/NIDCD P50DC014664-06A1, Co-Investigator, 2022(3) NIH/NIDCD P50DC014664-06A1, Co-Investigator, 2022
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ezequiel Gleichgerrcht, MD, PhD
From the Departments of Communication Sciences and Disorders (N.B., J.F.), and Psychology (C.R., R.N.N.), University of South Carolina, Columbia; Department of Health and Rehabilitation Sciences (J.W., E.G., S.K., J.F.), Medical University of South Carolina, Charleston; Department of Neurology (R.R., L.B.), Emory University, Atlanta, GA; Department of Neurology (A.E.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pharmacology and Therapeutics (S.S.K., C.d.B.), Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust (S.S.K., C.d.B.), Liverpool, United Kingdom.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Chris Rorden, PhD
From the Departments of Communication Sciences and Disorders (N.B., J.F.), and Psychology (C.R., R.N.N.), University of South Carolina, Columbia; Department of Health and Rehabilitation Sciences (J.W., E.G., S.K., J.F.), Medical University of South Carolina, Charleston; Department of Neurology (R.R., L.B.), Emory University, Atlanta, GA; Department of Neurology (A.E.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pharmacology and Therapeutics (S.S.K., C.d.B.), Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust (S.S.K., C.d.B.), Liverpool, United Kingdom.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
P50 DC014664 4/1/2016-3/31/2020 $11,394,899, Role Project Leader: Neuroimaging Core and Project 3R01 DC009659 10/1/2015-10/5/2019 $1,829,676, Role co-IR21 DC014170 05/2015-04/2017 $275,000, Role co-IR01 DC014021 10/6/2014-5/31/2019 $1,381,525, Role co-IU01 DC011739 Fridriksson (PI) 7/1/2012-6/31/2017 $1,381,525, Role co-ISouth Carolina SmartState Endowed Chair of Neuroimaging, Role PI
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Rebecca Roth, BA
From the Departments of Communication Sciences and Disorders (N.B., J.F.), and Psychology (C.R., R.N.N.), University of South Carolina, Columbia; Department of Health and Rehabilitation Sciences (J.W., E.G., S.K., J.F.), Medical University of South Carolina, Charleston; Department of Neurology (R.R., L.B.), Emory University, Atlanta, GA; Department of Neurology (A.E.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pharmacology and Therapeutics (S.S.K., C.d.B.), Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust (S.S.K., C.d.B.), Liverpool, United Kingdom.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Roger Newman-Norlund, PhD
From the Departments of Communication Sciences and Disorders (N.B., J.F.), and Psychology (C.R., R.N.N.), University of South Carolina, Columbia; Department of Health and Rehabilitation Sciences (J.W., E.G., S.K., J.F.), Medical University of South Carolina, Charleston; Department of Neurology (R.R., L.B.), Emory University, Atlanta, GA; Department of Neurology (A.E.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pharmacology and Therapeutics (S.S.K., C.d.B.), Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust (S.S.K., C.d.B.), Liverpool, United Kingdom.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Argye Elizabeth Hillis, MD, MA
From the Departments of Communication Sciences and Disorders (N.B., J.F.), and Psychology (C.R., R.N.N.), University of South Carolina, Columbia; Department of Health and Rehabilitation Sciences (J.W., E.G., S.K., J.F.), Medical University of South Carolina, Charleston; Department of Neurology (R.R., L.B.), Emory University, Atlanta, GA; Department of Neurology (A.E.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pharmacology and Therapeutics (S.S.K., C.d.B.), Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust (S.S.K., C.d.B.), Liverpool, United Kingdom.
Disclosure
Scientific Advisory Boards:
1.
Unpaid member of the Scientific Advisory Board, SnyderCenter for Aphasia Life Enhancement
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
Stroke, Associate Editor, 2014-2020; Deputy Editor (present); Aphasiology, Associate Editor, 2008-2022, Practice Update Neurology, Associate Editor, 2015-present
Patents:
1.
NONE
Publishing Royalties:
1.
Handbook of Adult Language Disorders, Taylor & Francis, 2015-2020
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIDCD RO1 DC05375 2003-current, PI(2) P50 DC014664, PI of project 2 and PI of clinical core, 2016-current(3)NIDCD, R01DC015466, PI, 2017-current(4)NINDS, R25NS06572, PI, 2009-present(5) NHLBI R01HL144751 Co-I 2021-present
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Serves on the Board of Directors of the World Stroke Organization (unpaid)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Simon S. Keller, PhD
From the Departments of Communication Sciences and Disorders (N.B., J.F.), and Psychology (C.R., R.N.N.), University of South Carolina, Columbia; Department of Health and Rehabilitation Sciences (J.W., E.G., S.K., J.F.), Medical University of South Carolina, Charleston; Department of Neurology (R.R., L.B.), Emory University, Atlanta, GA; Department of Neurology (A.E.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pharmacology and Therapeutics (S.S.K., C.d.B.), Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust (S.S.K., C.d.B.), Liverpool, United Kingdom.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Christophe de Bezenac, PhD
From the Departments of Communication Sciences and Disorders (N.B., J.F.), and Psychology (C.R., R.N.N.), University of South Carolina, Columbia; Department of Health and Rehabilitation Sciences (J.W., E.G., S.K., J.F.), Medical University of South Carolina, Charleston; Department of Neurology (R.R., L.B.), Emory University, Atlanta, GA; Department of Neurology (A.E.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pharmacology and Therapeutics (S.S.K., C.d.B.), Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust (S.S.K., C.d.B.), Liverpool, United Kingdom.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sigfus Kristinsson, PhD
From the Departments of Communication Sciences and Disorders (N.B., J.F.), and Psychology (C.R., R.N.N.), University of South Carolina, Columbia; Department of Health and Rehabilitation Sciences (J.W., E.G., S.K., J.F.), Medical University of South Carolina, Charleston; Department of Neurology (R.R., L.B.), Emory University, Atlanta, GA; Department of Neurology (A.E.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pharmacology and Therapeutics (S.S.K., C.d.B.), Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust (S.S.K., C.d.B.), Liverpool, United Kingdom.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Julius Fridriksson, PhD
From the Departments of Communication Sciences and Disorders (N.B., J.F.), and Psychology (C.R., R.N.N.), University of South Carolina, Columbia; Department of Health and Rehabilitation Sciences (J.W., E.G., S.K., J.F.), Medical University of South Carolina, Charleston; Department of Neurology (R.R., L.B.), Emory University, Atlanta, GA; Department of Neurology (A.E.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pharmacology and Therapeutics (S.S.K., C.d.B.), Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust (S.S.K., C.d.B.), Liverpool, United Kingdom.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
ssociate Editor:Neurobiology of Language
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
PI on two NIH grants. Co-I on several other NIH grants.
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Leonardo Bonilha, MD, PhD
From the Departments of Communication Sciences and Disorders (N.B., J.F.), and Psychology (C.R., R.N.N.), University of South Carolina, Columbia; Department of Health and Rehabilitation Sciences (J.W., E.G., S.K., J.F.), Medical University of South Carolina, Charleston; Department of Neurology (R.R., L.B.), Emory University, Atlanta, GA; Department of Neurology (A.E.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pharmacology and Therapeutics (S.S.K., C.d.B.), Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom; The Walton Centre NHS Foundation Trust (S.S.K., C.d.B.), Liverpool, United Kingdom.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
I am part of the editorial board of Epilepsy and Behavior. I do not receive financial compensation for this role.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
R01DC014021 (NIH/NIDCD)Bonilha (PI) 07/01/2014 – 07/01/2024Brain Connectivity Supporting Language Recovery in Aphasia. Major Goal: To investigate how residual structural connectivity enables recovery from aphasia in individuals who suffered a stroke.Role: PIU01DC017521 (NIH/NIDCD)Bonilha (MPI) 01/01/2019– 01/01/2024Speech Entrainment for Aphasia Recovery (SpARc).Major Goal: Phase II clinical trial to determine effect sizes and optimal dose of speech entrainment to treat non-fluent aphasia.Role: Corresponding MPIR01NS110347(NIH/NINDS)Bonilha (MPI) 07/01/2019 – 07/01/2024Predicting Epilepsy Surgery Outcomes Using Neural Network Architecture.Major Goal: To evaluate the relationship between neuronal network abnormalities and surgical outcomes in temporal lobe epilepsy.Role: Corresponding MPIP50 DC014664 (NIH/NIDCD)Fridriksson (PI) 04/14/2016 – 04/14/2021Center for the Study of Aphasia Recovery (C-STAR) P50 DC014664Major Goal: To evaluate mechanisms associated with language impairment and recovery after brain injury. (Co-Investigator).
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Busby [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Submitted and externally peer reviewed. The handling editor was Editor-in-Chief José Merino, MD, MPhil, FAAN.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Individual differences in neuroplastic recovery, Encyclopedia of the Human Brain, (758-774), (2025).https://doi.org/10.1016/B978-0-12-820480-1.00206-0
    Crossref
  2. Elucidating Multimodal Imaging Patterns in Accelerated Brain Aging: Heterogeneity through a Discriminant Analysis Approach Using the UK Biobank Dataset, Bioengineering, 11, 2, (124), (2024).https://doi.org/10.3390/bioengineering11020124
    Crossref
  3. Acceleration of brain aging after small-volume infarcts, Frontiers in Aging Neuroscience, 16, (2024).https://doi.org/10.3389/fnagi.2024.1409166
    Crossref
  4. Neuroanatomical Signature of the Transition from Normal Cognition to MCI in Parkinson's Disease, Aging and disease, (0), (2024).https://doi.org/10.14336/AD.2024.0323
    Crossref
  5. Distinct brain morphometry patterns revealed by deep learning improve prediction of post-stroke aphasia severity, Communications Medicine, 4, 1, (2024).https://doi.org/10.1038/s43856-024-00541-8
    Crossref
  6. Regional brain aging: premature aging of the domain general system predicts aphasia severity, Communications Biology, 7, 1, (2024).https://doi.org/10.1038/s42003-024-06211-8
    Crossref
  7. The Aphasia Recovery Cohort, an open-source chronic stroke repository, Scientific Data, 11, 1, (2024).https://doi.org/10.1038/s41597-024-03819-7
    Crossref
  8. Discourse- and lesion-based aphasia quotient estimation using machine learning, NeuroImage: Clinical, 42, (103602), (2024).https://doi.org/10.1016/j.nicl.2024.103602
    Crossref
  9. The effect of head motion on brain age prediction using deep convolutional neural networks, NeuroImage, 294, (120646), (2024).https://doi.org/10.1016/j.neuroimage.2024.120646
    Crossref
  10. Insights gained over 60 years on factors shaping post-stroke aphasia recovery: A commentary on Vignolo (1964), Cortex, 170, (90-100), (2024).https://doi.org/10.1016/j.cortex.2023.12.002
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

View Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share